On Nov 13, major Wall Street analysts update their ratings for $Bristol-Myers Squibb (BMY.US)$, with price targets ranging from $60 to $73.
Citi analyst Geoff Meacham maintains with a hold rating, and adjusts the target price from $55 to $60.
UBS analyst Trung Huynh maintains with a hold rating, and adjusts the target price from $54 to $60.
BMO Capital analyst Evan Seigerman upgrades to a buy rating, and adjusts the target price from $53 to $61.
Leerink Partners analyst David Risinger upgrades to a buy rating, and adjusts the target price from $55 to $73.
Furthermore, according to the comprehensive report, the opinions of $Bristol-Myers Squibb (BMY.US)$'s main analysts recently are as follows:
The unexpected update regarding emraclidine's Phase 2 from AbbVie has led to a revision of projections, with emraclidine being removed from the forecast model and an increase in Cobenfy estimates for Bristol Myers. As a result, the total revenue for 2033 is anticipated to rise by 7%. The overall conclusion is that this development does not alter the long-term revenue or earnings per share growth trajectory for either company.
The pivotal Phase 2 data for a competing firm's schizophrenia treatment was unexpectedly unsuccessful in showing a significant change from the baseline in the Positive and Negative Symptom Scale total score, which was anticipated to be a key asset from a major acquisition and was projected to generate substantial sales by the end of the decade, potentially rivaling Bristol Myers's own treatment. The outlook for Bristol Myers's treatment should be considerably improved in the long term, although there are still concerns about the loss of exclusivity in the near term.
The latest clinical outcomes for AbbVie's Emraclidine, failing to demonstrate a statistically significant benefit at the primary endpoint in its Phase 2 studies, have positioned Bristol Myers' Cobenfy in a favorable spot. With competitors facing setbacks due to underwhelming data, the focus is now solely on Bristol Myers to successfully launch Cobenfy.
Here are the latest investment ratings and price targets for $Bristol-Myers Squibb (BMY.US)$ from 4 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美东时间11月13日，多家华尔街大行更新了$施贵宝 (BMY.US)$的评级，目标价介于60美元至73美元。
花旗分析师Geoff Meacham维持持有评级，并将目标价从55美元上调至60美元。
瑞士银行分析师Trung Huynh维持持有评级，并将目标价从54美元上调至60美元。
BMO资本市场分析师Evan Seigerman上调至买入评级，并将目标价从53美元上调至61美元。
Leerink Partners分析师David Risinger上调至买入评级，并将目标价从55美元上调至73美元。
此外，综合报道，$施贵宝 (BMY.US)$近期主要分析师观点如下：
关于艾伯维公司emraclidine的第二阶段意外更新导致了预测的修订，emraclidine被移除出预测模型，并且对百时美施贵宝的Cobenfy估计进行了上调。因此，2033年的总营业收入预计将增长7%。总体结论是，这一发展不会改变两家公司长期的营业收入或每股收益增长轨迹。
一家竞争公司的精神分裂症治疗的关键第二阶段数据意外未能显示出与基线相比在阳性和阴性症状量表总体评分上有显著变化，这被预计为一次重大收购的关键资产，并预计在十年末产生可观的销售，可能会与百时美施贵宝自己的治疗形成竞争。虽然对于百时美施贵宝的治疗的长期前景应该有显着改善，但仍然存在关于短期内失去专属性的担忧。
最新的临床结果显示，艾伯维公司的Emraclidine在其第二阶段研究中的主要终点未能显示出统计学显著的益处，这让百时美施贵宝的Cobenfy处于有利位置。随着竞争对手因数据不佳而面临挫折，关注点现在全部集中在百时美施贵宝成功推出Cobenfy上。
以下为今日4位分析师对$施贵宝 (BMY.US)$的最新投资评级及目标价：
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
